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The expression of human endogenous retroviruses (HERVs) has been associated with
Multiple Sclerosis (MS). The MS-related retrovirus (MSRV/HERV-W) has the potential to
activate inflammatory immunity, which could promote both susceptibility and progression
toward MS. A connection between HERVs and MS is also supported by the observation
that people infected with the human immunodeficiency virus (HIV) may have a lower
risk of developing MS than the HIV non-infected, healthy population. This may be
due to suppression of HERV expression by antiretroviral therapies (ART) used to treat
HIV infection. In this pilot study, we compared RNA expression of the envelope gene
of MSRV/HERV-W, as well as Toll-like receptors (TLR) 2 and 4, in a small cohort of
HIV+ patients with MS patients and healthy controls (HC). An increased expression of
MSRV/HERV-Wenv and TLR2 RNA was detected in blood of MS patients compared
with HIV patients and HC, while TLR4 was increased in both MS and HIV patients.
There was, however, no difference in MSRV/HERV-Wenv, TLR2 and TLR4 expression
between ART-treated and -untreated HIV patients. The viral protein Env was expressed
mainly by B cells and monocytes, but not by T cells and EBV infection could induce
the expression of MSRV/HERV-Wenv in Lymphoblastoid cell lines (LCLs). LCLs were
therefore used as an in vitro system to test the efficacy of ART in inhibiting the expression
of MSRV/HERV-Wenv. Efavirenz (a non-nucleoside reverse transcriptase inhibitor) alone
or different combined drugs could reduceMSRV/HERV-Wenv expression in vitro. Further,
experiments are needed to clarify the potential role of ART in protection from MS.
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INTRODUCTION
Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS).
The cause of MS is not known, but genetic linkage studies and the beneficial effect of
immunomodulatory treatments indicate that the disease is immune-mediated (1). Activation of
autoimmune processes in MS results from the interaction of genetic and environmental factors
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(which include Herpes viral infections, smoking, and vitamin D
deficiency) (2). An additional risk factor that has been identified
is the expression of human endogenous retroviruses (HERVs) of
the HERV-W family (3, 4).
HERVs are viruses that have integrated into human germ
line cells between 30 and 70 million years ago, becoming
part of human DNA and being then transmitted through
subsequent generations. Indeed, almost 8% of the human genome
is constituted of groups of HERVs, ranging in copy number from
one to many thousands (5).
It has been reported that endogenous retroviruses can engage
the innate immune system, and in particular Toll-like receptors
(TLRs) (6). Both in vitro and in vivo experiments have illustrated
the immunopathogenicity induced by MS-associated retrovirus
(MSRV/HERV-W) proteins through direct interaction with
TLR4 (7–9). Upon TLR4 engagement by HERVs, signaling
pathways are activated that lead to secretion of pro-inflammatory
cytokines, such as IL-1β, IL-6, and TNF-α (7).
Comorbidity of Human Immunodeficiency Virus (HIV) and
MS is very rare (10). Gold et al. examined the association between
HIV and MS using an English medical database with a cohort of
21,207 HIV-positive patients and 5,298,496 controls stratified by
age, sex, year of first hospital admission, a region of residence,
and socioeconomic status. They calculated that the risk rate ratio
of developing MS was significantly lower in people infected than
in those not infected by HIV (0.38; 95% CI 0.15 to 0.79) (10). The
authors discussed two different hypotheses that could explain this
inverse correlation. The first is related to the HIV viral infection
itself. HIV is an infectious retrovirus that if left untreated causes
suppression of the immune system, eventually leading to life-
threatening infections and cancers. Primarily, HIV targets the
CD4+ lymphocytes cells, which are in their turn thought to be
involved in the pathogenesis of MS. The reduction of CD4+ T
cells in infected people could, therefore, lower any autoimmune
response against the CNS. However, clinical cases where patients
have developed MS or CNS demyelinating disorders after HIV
infection have been reported (11–13), suggesting thereby that
HIV may not protect from MS. Conversely, as HIV-infected MS
patients who received Antiretroviral Therapy (ART) had a less
severe clinical course of MS (11, 14, 15), this would suggest that
if an inverse association between the infection and MS exists, it
may in fact be due to the effect of ART on MS. Unfortunately,
Gold et al. did not report which patients were taking retroviral
treatments, but rather assumed that most of the patients were on
ART, as one would expect to be the case for developed countries
(10).
Antiretroviral drugs are classified based on the phase of
the retroviral life-cycle that each drug targets. Typically, a
combination of drugs from different classes are used to optimize
their efficacy in the treatment of HIV infection [termed
ART, or combination anti-retroviral therapy (cART)]. These
antiretroviral therapies act not only against HIV but probably
also inhibit endogenous retroviruses, which thereby could
potentially prevent the development of MS. In line with this
contention, a phase II clinical trial (INSPIRE) studying the effect
of the integrase (enzyme that inserts the viral genome into the
DNA of the host cell) inhibitor Raltegravir on relapsing-remitting
(RR)-MS patients has been completed. Unfortunately, this trial
did not show any impact of the drug onMS inflammatory activity
detected by MRI (16). However, as HERVs are already integrated
into the genome, they may not be affected by an integrase
inhibitor.
In the current study, we aimed to test the hypothesis that ART
can reduce the expression of HERVs. A small cohort of HIV+
patients who were or were not on ART was recruited to study in
vivo the effect of antiretroviral drugs on the expression of human
MSRV/HERV-W. In parallel, the same classes of the drug were
used to test their efficacy in MSRV/HERV-W inhibition in vitro,
treating Lymphoblastoid cell lines (LCL).
MATERIALS AND METHODS
Human Blood Samples
Blood samples from patients attending Nottingham University
Hospitals NHS Trust were collected in PAXgene Blood RNA
tubes (Qiagen) and directly stored at −80◦C and later used for
gene expression analysis. MS diagnosis was established according
to McDonald’s criteria (17), and HIV infection was certified at
the Microbiology Department at the same hospital. All patients
and HCs signed informed consent for which ethical approval
was obtained. Patients and HC age, gender and clinical status are
presented in Table 1.
RNA Extraction and cDNA Synthesis
Total RNA was purified using the PAXgene Blood RNA kit
(Qiagen) following the manufacturer’s instructions. The RNA
was treated with DNase to remove trace amounts of bound DNA.
After the wash steps, RNA was extracted in the elution buffer
provided with the kit and stored at −80◦C. RNA concentration
was determined by measuring the absorbance at 260 nm using
NanoDrop ND-100 (Thermo Scientific). For making cDNA,
0.5 µg RNA samples, 2 µl Random hexamers and 1 µl
dNTPs mix (stock solution 10mM) (all Promega) were mixed,
followed by a 5min incubation at 65◦C for first strand cDNA
synthesis. A master mix containing RNase inhibitor (Promega,
United Kingdom), DTT (0.1M) and 5X First-Strand Buffer
was added, along with Superscript III RT (220 U/µl) (all from
Invitrogen, United Kingdom). Negative controls replacing the
RNA template or the RT with DNase/RNase free H2O were
included. Samples were incubated as followed: 5min at 95◦C,
60min at 50◦C, and 25min at 70◦C. cDNA was stored at−80◦C.
Real-Time RT-PCR
After titration of different cDNA dilutions, 1:2 DNase/RNase
free H2O dilution was selected. Relative quantification was
performed using Hydroxymethylbilane Synthase (HMBS) as
housekeeping gene. Nine hundred nanomolar of probe/forward
and reverse primer mix of MSRV//HERV-Wenv (designed as
reported previously in the literature (18), TLR4, TLR2, and
HMBS (TaqMan, Invitrogen) were used. All samples were run in
duplicates. RT- PCR reactions were performed using the 7900HT
Fast Real-Time PCR system (Applied Biosystems) in 96-well
plates. The following incubation protocol was imposed: 10min
at 95◦C and 40 cycles of 10 s at 95◦C followed by 30 s at 60◦C.
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TABLE 1 | Information on subjects in the study.
Subject Age Gender Ethnicity
(A) INFORMATION ON HC
HC 1 32 M Caucasian
HC 2 44 F Caucasian
HC 3 47 F Caucasian
HC 4 38 F Caucasian
HC 5 27 M Caucasian
HC 6 54 M Caucasian
HC 7 31 F Arabic
HC 8 30 M Caucasian
HC 9 51 F Jamaican
HC 10 42 M Caucasian
HC 11 27 M Caucasian
HC 12 44 M
HC 13 60 F Caucasian
HC 14 44 F Caucasian
HC 15 55 F Caucasian
HC 16 28 M Caucasian
HC 17 60 M Caucasian
HC 18 53 F Caucasian
HC 19 59 Caucasian
HC 20 31 M Indian
HC 21 27 M Caucasian
HC 22 44 F Caucasian
Subject Age Gender Ethnicity Disease course Current DMT Disease duration (years)
(B) INFORMATION ON MS PATIENTS
MS 1 41 F Caucasian RR no 5
MS 2 56 F Caucasian no 8
MS 3 38 F Caucasian RR no 3
MS 4 54 M Caucasian RR no 6
MS 5 55 F SP no
MS 6 46 F SP no
MS 7 44 F RR no
MS 8 46 F RR no
MS 9 52 F SP no
MS 10 21 M RR no
MS 11 61 F SP no
MS 12 46 F SP no
MS 13 51 F Caucasian RR no 1
MS 14 56 F Caucasian PP no 8
MS 15 56 F no
MS 16 52 F Caucasian SP no 6
MS 17 46 F Caucasian no
MS 18 48 F Caucasian no
MS 19 49 M Caucasian RR β-interf 1
MS 20 45 F Caucasian RR no
MS 21 41 F Caucasian no 2
MS 22 42 M Caucasian RR β-interf 1
Subject Age Gender Ethnicity Art Duration on art Viral load
(C) INFORMATION ON HIV PATIENTS
HIV 1 46 M Greek no – 30,010
HIV 2 31 M Jamaican no – 608
HIV 3 48 M White British Tdf, FTC, DRV, Rit 4 years <40
HIV 4 49 F White British ABC, 3TC, EFZ 13 years <40
HIV 5 34 F Filipino no – 106,361
HIV 6 42 M White British Tdf, FTC, EFZ 3 years <40
HIV 7 57 M White British Tdf, FTC, EFZ 9 years <40
HIV 8 47 F White British AZT, 3TC, EFZ 9 years <40
HIV 9 44 M White British Tdf, FTC, DRV, Rit 12 years <40
RR, relapsing-remitting; PP, primary-progressive; SP, secondary-progressive.
ARTs (antiretroviral treatments):
NRTIs: ABC: Abacavir, AZT: Zidovudine, 3TC: Lamivudine, FTC: Emtricitabine.
NtRTI: Tdf: Tenofovir disoproxil.
NNRTIs: EFZ: Efavirenz.
PIs: DRV: Darunavir, Rit: Ritonavir.
Subject HC 15 (italics) was used as reference for relative quantification of MSRV/HERV-Wenv, TLR4 and TLR2 gene expression.
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Themean Ct values of MSRV//HERV-Wenv, TLR4 or TLR2 were
normalized compared to the Ct value of HMBS. Calculation of
the relative amounts of MSRV//HERV-Wenv, TLR4 or TLR2
was performed using the 211Ct method with one HC used
as a standard (HC15, selected for the high amount of RNA
concentration). The reference sample HC15 was analyzed in all
the different plates as an inter-run calibrator. Any change in gene
expression between HC,MS and HIV patients compared to HC15
was expressed as a fold change using the formula below:
Fold increase for each patient compared to the HC15 = 2
11Ct
Where for each patient:
11Ct = [(CtGI − CtHMBS)−1CtHC15]
GI = MSRV env, TLR4, TLR2
1CtHC15 = 1Ct reference gene(HC15)
= (Ct GIHC15 − CtHMBSHC15)
Extracellular FC Staining for HERV-W
Peripheral blood mononuclear cells (PBMC) were isolated from
blood donors using Ficoll density gradient centrifugation. Surface
staining for Pe-Cy7 anti-CD3 (UCHT1), PE anti-CD14 (M5E2),
and Pe-Cy5 anti-CD20 (2H7) all from BD was performed
on PBMC. HERV-W was detected using primary anti-HERV-
WEnv rabbit polyclonal antibody (Allele Biotech) with secondary
CF488A goat anti-rabbit antibody (Sigma-Aldrich). A control
with only secondary CF488A goat anti-rabbit antibody was
included, and Fluorescence minus one (FMO) samples were used
to set the gating. Cells were incubated in the dark for 30min at
4◦C. After incubation, cells were washed twice with FACS buffer
and centrifuged at 300 g for 6min. Cells were then fixed with 500
µl Fixation buffer (2% paraformaldehyde, BD). Blue Live/dead
marker (ThermoFisher Scientific) was included in the staining to
assess the viability. Cells were analyzed by FC using LSRII flow
cytometer (BD Biosciences, USA) and FlowJo software (version
V10, FlowJo, LLC, United States).
Activation of B Cells With CpG and
Generation of LCL
CD20+ B cells were purified from PBMC by positive selection
using a CD20+ cell isolation kit (Miltenyi Biotec) following the
manufacturer’s instructions. Collected CD20+ and CD20– cells
were counted with haemocytometer. Purity of CD20+ cells was
assessed using an anti-CD20 Ab by FC. 106 CD20+ isolated B
cells were cultured in 400 µl of complete medium [Roswell Park
Memorial Institute medium (RPMI) with 10% fetal calf serum
(FCS), 100 units penicillin−1 mg/ml streptomycin (pen/strep),
20mM L-glutamine all from Sigma- Aldrich] with 30µg/ml of
CpG OND 2006 (Invivogen, sequence “TCG TCG TTT TGT
CGT TTT GTC GT”) in 48-wells plate for 24 h. Activation of
CD20+ cells was assessed using an anti-CD86 Ab by FC.
Five to 10 × 106 of isolated PBMC were centrifuged at
300 g for 10min. Three ml of supernatant from a B95.8 EBV
infected marmoset B cell line (19) (kindly donated by Jill
Brooks, Birmingham, UK) was collected from the same batch
and centrifuged at 200 g for 5min. The B95.8 supernatant was
filtered through a 0.45µm filter on the PBMC pellet, and
the PBMC mixed with the virus were incubated overnight at
37◦C. After centrifugation, the supernatant was discarded, and
infected PBMC were re-suspended in complete RPMI+ 1µg/ml
Cyclosporine A (Sigma). LCL was established from 6 different
healthy donors and was expanded in culture.
Drug Treatment
Reverse transcriptase inhibitors inhibit HIV reverse
transcription, and are divided into Nucleoside Reverse
Transcriptase Inhibitors (NRTI), Nucleotide Reverse
Transcriptase Inhibitors (NtRTI), and Non-Nucleoside Reverse
Transcriptase Inhibitors (NNRTI). NRTI and NtRTI act as
competitive substrate inhibitors, while NNRTI inhibits reverse
transcriptase by binding to an allosteric site of the enzyme.
Integrase inhibitors (II) inhibit the viral enzyme integrase, and
protease inhibitors block the viral protease enzyme. Drugs were
purchased from Sigma-Aldrich and dissolved in DMSO. One
million LCL from different donors were treated with Lamivudine
(NRTI), Tenofovir (NtRTI), Daranuvir (PI), Efavirenz (NNRTI)
and Raltegravir (II) at concentrations of 10, 1, and 0.1µM for
5 days. At day 3, the medium was changed, and fresh drugs
were added. The range of different doses was chosen based on
datasheet indication and previous publications where similar
tests in vitro were used to test antiretroviral efficacy against HIV
(20, 21) or porcine endogenous retroviruses (22).
Statistical Analysis
The data were presented as medians and interquartile range, and
statistical analysis was performed using GraphPad prism v7 as
reported in the figure legends.
RESULTS
Expression of MSRV/HERV-W in MS and
HIV Patients
Many studies have been reported in the literature showing the
increased expression of MSRV/HERV-W in MS patients (4),
but the expression of MSRV/HERV-W in HIV-infected patients
has never been investigated until now. In this study, total RNA
was extracted from PAXGENE tubes (total blood) of 22MS
patients, 22 HC and 9 HIV-infected patients (Table 1, average
age MS = 47.5, HC = 42.8, HIV = 44.2). Relative quantification
of MSRV/HERV-Wenv, TLR4 and TLR2 gene expression was
assessed with real-time quantitative RT-PCR using the reference
gene HMBS and the HC subject number 15 (HC 15, Table 1) as
1. The expression of MSRV/HERV-Wenv in the MS group was
significantly higher compared with HC (p= 0.019) and HIV (p<
0.001) (Figure 1A). MSRV/HERV-Wenv expression was similar
in HIV patients and HC.
TLR4 expression was significantly higher in MS and HIV
compared to HC (respectively p = 0.04 and p = 0.001)
(Figure 1B), while TLR2 was increased only in MS patients
(Figure 1C).
The HIV patients were then grouped into treated with
antiretroviral drugs patients (n = 6) and untreated patients
(n = 3; Table 1C). No difference in MSRV/HERV-Wenv, TLR4
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FIGURE 1 | MSRV/HERV-Wenv, TLR4 and TLR2 gene expression in HIV and MS patients and in healthy control (HC). MSRV/HERV-Wenv and TLR4 expression were
evaluated by relative quantification RT-PCR using the 2−11Ct method. Fold changes of (A) MSRV/HERV-Wenv, (B) TLR4, and (C) TLR2 expression of each individual
sample in each group are illustrated in dots. HIV patients were compared to HC and MS using HC15 as a reference gene. Medians and interquartile range are
indicated by bars (HC, n = 22, MS, n = 22, HIV, n = 9; Kruskal-Wallis Test with Dunn’s multiple comparison test).
and TLR2 expression between the two groups was found
(Figure 2).
Expression of HERV-WEnv Protein in
Different Cell Types of MS and HC
We next aimed to characterize the cells that express
MSRV/HERV-W. HERV-W Env can be translated into protein
and detected on the surface of cells. HERV-W Env protein
expression was detected on the cell surface of immune cells
from HCs using a primary anti-HERV-W Env antibody and a
CF488A-labeled secondary antibody by Flow Cytometry (23).
HERV-W Env was expressed by 20% of PBMC of which mainly
by CD20+ B cells and CD14+ monocytes. CD3+ T cells were
negative (Figure 3).
Comparison of HERV-W Env protein expression in different
cell subtypes (total PBMC, T cells, B cells, and monocytes)
derived from 10MS (6 RR-MS, 1 PP-MS, 3 SP-MS) patients and
six age-matched HC, showed no difference in HERV-W Env
protein levels (Figure 3B).
EBV is strongly associated with MS (24). In vitro, the
expression of MSRV/HERV-W genes/proteins is activated by
some viruses such as EBV, herpes simplex virus type 1 or by
influenza virus (25). One study showed that binding of the
EBV surface glycoprotein gp350 could activate the expression
of MSRV/HERV-W in cells from blood and brain (23). EBV-
immortalized B-lymphoblastoid cell lines (LCL) were generated
in vitro. LCL represents a tissue culture model for human B cell
transformation and virus latency, and they express the genes of
the latency III program of EBV. To investigate if EBV could
activate MSRV/HERV-W, MSRV/W env RNA expression was
measured in isolated CD20+ cells, CD20+ cells activated with
CpG (TLR9 agonist), LCL and CD20– cells from 5 different HC
donors. Quantification of MSRV/HERV-W env gene expression
relative to the mean of the expression in CD20+ cells (considered
as 1) was assessed with real-time RT-PCR. LCL showed 12-
fold increase in MSRV/HERV-W expression compared to the
uninfected CD20+ cells (Figure 4A). Similarly, CpG activation
induced the expression of MSRV/HERV-W env.
Relative MSRV/HERV-W env RNA expression was measured
in LCL from 3 HC and from 3MS to test if MS patients express
more MSRV/HERV-Wenv RNA after EBV infection compared to
HC. No difference was detected between LCL from HC and MS
by real-time RT-PCR (Figure 4B).
Expression of MSRV/HERV-W in LCL
Treated With Different Antiretroviral Drugs
in vitro
MSRV/HERV-Wenv expression was then analyzed in cells treated
in vitro with antiretroviral drugs. MSRV/HERV-Wenv RNA
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FIGURE 2 | MSRV/HERV-Wenv, TLR4 and TLR2 gene expression in HIV patients categorized in treated (ART) and untreated patients (NO ART). MSRV/HERV-Wenv,
TLR4 and TLR2 expression were evaluated by relative quantification RT-PCR using the 2−11Ct method. Fold changes of (A) MSRV/HERV-Wenv, (B) TLR4, and (C)
TLR2 expression of 9 HIV patients were categorized in treated (ART) and untreated (NO ART) patients are illustrated in dots. Medians and interquartile range are
indicated by bars (ART, n = 6, NO ART, n = 3; Mann-Whitney Test).
expression was analyzed by RT-PCR in LCL treated with the same
classes of drugs that the patients were taking. The drugs used
were Lamivudine (NRTI), Tenofovir (NtRTI), Daranuvir (PI),
Efavirenz (NNRTI) and Raltegravir (II). LCL from 3 HC subjects
were treated with drugs at the concentrations of 10, 1, and 0.1µM
for 5 days (Figure 5). Only Efavirenz (NNRTI) decreased the
expression of MSRV/HERV-Wenv at the highest concentration
(Figure 5D).
Cells were then treated with drug combinations, to mimic
ART in vivo. Detection by RT-qPCR showed a reduced expression
of MSRV/HERV-Wenv RNA (Figure 6A). Similarly, HERV-
W/HERV-WEnv protein showed by FC a trend of reduction in
the presence of 1µM of combined drugs (Figures 6B,C).
DISCUSSION
The expression of MSRV/HERV-Wenv was evaluated in a
small number of MS patients, HIV-infected patients, and HC.
Expression of MSRV/HERV-Wenv in MS patients was higher
compared to HC, as already reported in the literature (4). HERV-
W Env was expressed in whole PBMC, at a high level in B cells
andmonocytes. No expression of HERV-WEnvwas detected in T
cells. These results are in line with previous publications (23, 26)
and underline a key role of B cells and monocytes in HERV-W
expression. Despite increased expression of MSRV/HERV-W env
mRNA in MS patients by RT-PCR, HERV-W Env protein was
detected in all samples of MS andHC using FC with no difference
in the number of HERV-W positive cells between the two groups.
At the protein level, no antibody has been developed yet to
discriminate MSRV Env from Syn-1 (18). Moreover, the issue
of HERV-W complexity extends to studies of HERV protein
expression: it often remains unclear as to which genomic locus
the observed HERV proteins are derived from and therefore,
whether the precise identity of the protein recognized by the
HERV-W Env antibody can be established. This could explain
why HERV-W is expressed in similar percentage in both groups:
the antibody could detect either MSRVenv or Syn-1 or both
together.
As reported in the literature, EBV infection induces the
expression of MSRV/HERV-W env (25). However, the activation
of the retrovirus can occur not only in the presence of EBV,
but also when B cells are activated with CpG. Thus, bacterial
or synthetic unmethylated CpG ODNs mediate their effects
by interacting with TLR9, which is expressed in pDC and
B cells. Activation of B cells by CpG leads to proliferation,
production of antibodies and cytokines. It is possible therefore
that MSRV/HERV-W activation is induced either directly by
TLR9 activation as in the presence of a bacterial infection or
by pro-inflammatory cytokines expressed by CpG-activated B
cells. In line with this contention, it has been reported that pro-
inflammatory stimuli, such as IFN-γ and TNF-α can activate
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FIGURE 3 | Expression of HERV-WEnv protein in different immune cells in HC and MS by Flow Cytometry. (A) Representative dot plot of the expression of HERV-WEnv
in gated CD20+ and CD3+ lymphocytes and CD14+ monocytes. The staining with only secondary CF 488A anti-rabbit antibody (without anti-HERV-WEnv primary
Ab) was used as negative control. (B) Expression of HERV-WEnv was detected in total PBMC, CD3+ T cells, CD20+ B cells and CD14+ monocytes from 10MS
patients and 6 HC. Percentage of positive cells is illustrated in dots. Medians and interquartile range are indicated by bars (n MS = 10, n HC = 6; Mann-Whitney Test).
MSRV/HERV-W env expression in B cells (23). MSRV/HERV-
W env expression in LCL was not different from HC and
people with MS, suggesting that EBV infection may potently
induce expression of MSRV/HERV-Wenv and mask the original
difference in MSRV/HERV-W env expression between B cells of
HC and MS patients.
Expression of MSRV/HERV-W env in HIV-infected patients
was similar to HC but was significantly lower than in MS
patients. The relationship between exogenous and endogenous
retroviruses is of relevance to human health and disease. All
retroviruses have a similar genetic make-up, and homologous
proteins encoded by one retrovirus could theoretically perform
comparable functions for another member of the family and
could thus complement a defective virus (27). Indeed, it has
been reported that HIV, through its protein TAT, increases the
expression of MSRV and HERV-K, as well as TLR4, in isolated
B cells, NK cells and monocytes in vitro (28). A reduction of
HERV-K expression in people who received suppressive ART has
been reported (29, 30), but other HERV families have not been
investigated. It is unclear whether HERV-K was directly inhibited
by the antiretroviral drugs, or whether the loss of activation by
HIV was responsible for the reduction of HERV-K viral load. It is
possible that the inhibition of the RT in some way affects also the
transcription of the HERV RNA. Although there is no evidence
that HERV-W can function as a retrovirus capable of retro-
transcription, some HERVs, and in particular HERV-K, can (31).
Protease inhibitors targeted at HIV are not active against HERV-
K (32), but other classes of antiretroviral drugs, in particular the
ones that target the RT enzyme, might be. Interestingly, the non-
nucleoside RT inhibitors Nevirapine and Efavirenz have already
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FIGURE 4 | MSRV/HERV-Wenv expression increases in LCL and CpG activated cells. (A) MSRV/HERV-Wenv expression was evaluated by relative quantification
RT-PCR using the 2-11Ct method. Fold changes of MSRV/HERV-Wenv in isolated CD20+ cells, CpG activated CD20+ cells, LCL (B-lymphoblastoid cell line) and
CD20– cells are illustrated in dots. Medians and interquartile range are indicated by bars (n = 5, Kruskal-Wallis Test with Dunn’s multiple comparison test). (B)
MSRV/HERV-Wenv expression was evaluated by relative quantification RT-PCR using the 2−11Ct method. Fold changes of MSRV/HERV-Wenv in LCL from HC and
MS patients are illustrated in dots. Medians and interquartile range are indicated by bars (n HC = 3, n MS = 3; Mann-Whitney Test).
been shown to inhibit efficiently the normal endogenous RT
activity that is detectable in many human cell lines and leukemic
cells (33, 34), suggesting a possible efficacy of this drug class in
the inhibition of HERVs.
The results of this pilot study are somewhat conflicting with
the original hypothesis that ART would reduce the expression
of HERVs, but our data are potentially explainable with
consideration of the biology of the system. HIV patients did
not show an increase in HERV-W expression when compared
with healthy controls. This is possibly explained by a mismatch
between the cell types that produce HERV-W (primarily
monocytes and B cells) and those that are affected by HIV
(primarily T cells). In this study, RNA was extracted from HIV
patients from total peripheral blood and is not representative
of a specific cell type. During HIV infection, there is an
alteration in immune cell populations [e.g., with B cells there
is hyper activation, as well as increased apoptosis that results
in B cell exhaustion (35)]. Therefore, it is possible that in HIV
patients MSRV/HERV-W env expression increases in some cell
subpopulations, but this change might not detectable in whole
blood. Moreover, RT-qPCR may not be the best method to detect
MSRV expression (4, 36, 37).
When HIV patients were divided into ART-treated and
untreated, no difference was found between the two groups.
However, due to the low number of HIV patients not on ART
treatment (n = 3), we cannot finally confirm that ART in vivo
does not affect MSRV/HERV-W expression.
Analyzing the patients’ HIV viral load, there was no
correlation between HIV viral load and MSRV/HERV-Wenv
expression (Table 1). It is possible that the different ethnicities
of untreated HIV patients (Jamaican, Greek, and Filipino) and
those treated (all white British) could influence the expression
of MSRV/HERV-W env on the basis of genetic differences. MS
patients in our studies were also mainly white British.
On the other hand, TLR4 expression was higher in both
MS and HIV patients compared with HC. This is potentially
due to the recognition of retroviruses, endogenous for MS and
exogenous for HIV, as a viral antigen by the TLR system (7, 8).
Indeed, it has been reported that myeloid dendritic cells from
HIV patients had an increased expression of TLR2 and TLR4
compared to HC (37). Hernandez et al. also showed that the
expression of TLR4 in cells from untreated patients was higher
than in treated and that in monocytes there was a positive
correlation between both the expression of TLR2/4 and viral load,
but no correlation with CD4+ T cell numbers (38). In our study
TLR2 was found to be increased only in MS patients, as already
reported in the literature (39, 40), but not in HIV patients. This
might be due to the increased MSRV/HERV-W env expression
(6), or to other infections (39).
In a move to identify the in vitro effects of different
concentrations of drugs used by the patients on LCLs, we have
recorded that only 10M Efavirenz (NNRTI) induced reductions
in MSRV/HERV-W env expression. However, there was no clear
evidence of inhibition in patients on NNRTI drugs as part of the
ART mix treatment (Table 1).
When LCLs were treated with a combination of drugs
a reduction of MSRV/HERV-W env RNA was detected
(Figure 4A). This would suggest that a synergy between different
drug classes is required to produce a measurable decrease in
HERV-W expression, a contention which is in line with the
demonstrable efficacy of ART against HIV as opposed to single
drug therapy. Again, this effect was not seen in the HIV samples
though this finding could have been accounted for by a) the
mismatch between affected cells and total blood cell population
described above; b) individual patient variability, and c) the small
number of patients on each combination of drugs.
The number of HIV patients in this pilot study was too
small to draw definite conclusions about the association of HIV
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FIGURE 5 | Efavirenz decreases the expression of MSRV/HERV-Wenv. LCL from 3 different healthy donors were treated with 0.1, 1, and 10µM of (A) Lamivudine,
(B) Tenofovir, (C) Daranuvir, (D) Efavirenz, and (E) Raltegravir for 5 days. CTRL (Controls) represent LCL treated only with DMSO. MSRV/HERV-Wenv expression was
evaluated by relative quantification RT-PCR using the 2−11Ct method and is illustrated in dots (n = 3; Friedman test).
with MSRV and the role of ART. It was particularly difficult to
enroll untreated HIV patients. Until larger studies are conducted,
we can at this stage only speculate about these mechanisms.
Therefore, larger cohorts of HIV patients are much needed to
recruit to identify whether ART has a role in protecting from
MS.
In conclusion, HIV-infected patients had lower expression of
MSRV/HERV env than MS patients, regardless of ART status.
Among ARTs, Efavirenz may reduce the expression of HERVs,
warranting further investigations to clarify the potential role of
ART in protecting fromMS.
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